ACCURACY
Out of 100 cases , 6 more correctly classified
77.6%Pathologists alone
83.9%
DiaKwant® PD‑L1 CPS and TPS
Review the tumor regions and cell counts behind CPS and TPS to check how the score was calculated.
CE MARKED UNDER IVDR, CLASS C, IN THE EUResearch Use Only outside the EU
VALIDATED SCORING SCOPE
Pan-organ PD-L1 scoring.
- CPS
- Breast · Head and neck · Gastrointestinal · Cervix
- TPS
- Lung · Urothelial
HOW IT WORKS
From slide
to reviewable score.
INPUT
Whole-slide image
Access the slide for quantification directly through your supported image management system.
PD‑L1
Review the tumor regions and cell counts behind CPS and TPS to check how the score was calculated.
REVIEW
Reviewable quantification result
The assay returns the score and supporting counts alongside the heatmap for expert review.
AVAILABLE ON
EVALUATION PROTOCOL
Tested against
expert consensus.
DiaKwant® AI alone- PathologistsWithout AI
Pathologists + DiaKwant® Same readers, after a washout phase
REFERENCE
Consensus score3 expert pathologists from 3 laboratories. Discordances are resolved by discussion.- 2studies
- 291cases
- 4tumour types
- 3expert pathologists set the reference
Pathologists alone
Out of
SENSITIVITY
Out of 100 positive cases, 11 more detected
78.5%Pathologists alone
89.6%
AGREEMENT BETWEEN
From moderate to excellent reliability
MODERATE 0.5–0.75GOOD 0.75–0.9EXCELLENT > 0.9
0.763Expert consensus0.705Pathologists alone0.904Pathologists + DiaKwant®
Each dot is one case out of 100. Boulagnon-Rombi C. et al., Impact de l’assistance par intelligence artificielle sur le scoring
PUBLICATIONS AND ABSTRACTS
Evidence for PD‑L1.
Studies and congress abstracts listing PD‑L1 as a biomarker. The full list is on the Resources page.
All publications ↗︎Impact of artificial intelligence assistance on combined PD-L1 scoring on whole immunohistochemical slide image of tumours
Clinical evaluation of an automated pan-organ combined PD-L1 scoring using artificial intelligence on immunostained whole-slide images
Programmed death-ligand 1 (
Evaluation of AI-assisted PD-L1 CPS scoring in immunostained pan-organ tumor whole-slide images.
FAQ
Practical
questions.
01What does DiaKwant PD‑L1 calculate?
DiaKwant PD‑L1 calculates a Combined Positive Score (CPS) or a Tumor Proportion Score (TPS), depending on the organ being assessed.
02Which cancers use CPS and which use TPS?
CPS is used for breast, head and neck, gastrointestinal and cervical cancers. TPS is used for lung and urothelial cancers.
03Is the PD‑L1 analysis automated?
Yes. The quantitative analysis is automated: DiaKwant processes the whole-slide image and returns the calculated score.
04What information can the pathologist review?
The pathologist can review the cell counts behind the score and a heatmap showing where positive cells were identified on the slide.
05Does DiaKwant replace the pathologist?
No. DiaKwant is a diagnostic aid. The result must be reviewed by a qualified pathologist, who retains full responsibility for the final interpretation and report.
06How can a laboratory confirm technical compatibility?
Technical compatibility depends on your laboratory's scanner and image management configuration. Contact the DiaDeep team to confirm compatibility for your validated setup.
PD‑L1 ON YOUR SLIDES
See DiaKwant® PD‑L1 at work on your own anonymized slides.
Discuss your scoring context and validated technical configuration with the DiaDeep team.
Try it on your cases ↗︎Apply to Club Quanti ↗︎